Insulet Corporation which can be found using ticker (PODD) have now 20 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $285.00 and $185.00 with the average target price sitting at $240.34. Given that the stocks previous close was at $232.03 this would indicate that there is a potential upside of 3.6%. Also worth taking note is the 50 day moving average now sits at $207.41 while the 200 day moving average is $192.18. The company has a market capitalization of 16.32B. The price for the stock stands currently at: $232.75 USD
The potential market cap would be $16,903,851,411 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 42.01, revenue per share of $26.78 and a 6.85% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
